BACKGROUND: Neoadjuvant chemotherapy for early breast cancer can avoid mastectomy by shrinkage of tumour volume. This review assesses the effectiveness of neoadjuvant chemotherapy on clinical outcome. METHODS: All randomized trials comparing neoadjuvant and adjuvant chemotherapy for early breast cancer were reviewed systematically and meta-analyses were performed. RESULTS: Fourteen studies randomizing 5500 women were eligible for analysis. Overall survival was equivalent in both groups. In the neoadjuvant group, the mastectomy rate was lower (relative risk 0.71 (95 per cent confidence interval (c.i.) 0.67 to 0.75)) without hampering local control (hazard ratio 1.12 (95 per cent c.i. 0.92 to 1.37)). Neoadjuvant chemotherapy was associated fewer adverse effects. CONCLUSION: Neoadjuvant chemotherapy is an established treatment option for early breast cancer. Copyright (c) 2007 British Journal of Surgery Society Ltd.
BACKGROUND: Neoadjuvant chemotherapy for early breast cancer can avoid mastectomy by shrinkage of tumour volume. This review assesses the effectiveness of neoadjuvant chemotherapy on clinical outcome. METHODS: All randomized trials comparing neoadjuvant and adjuvant chemotherapy for early breast cancer were reviewed systematically and meta-analyses were performed. RESULTS: Fourteen studies randomizing 5500 women were eligible for analysis. Overall survival was equivalent in both groups. In the neoadjuvant group, the mastectomy rate was lower (relative risk 0.71 (95 per cent confidence interval (c.i.) 0.67 to 0.75)) without hampering local control (hazard ratio 1.12 (95 per cent c.i. 0.92 to 1.37)). Neoadjuvant chemotherapy was associated fewer adverse effects. CONCLUSION: Neoadjuvant chemotherapy is an established treatment option for early breast cancer. Copyright (c) 2007 British Journal of Surgery Society Ltd.
Authors: Zeljko Vujaskovic; Dong W Kim; Ellen Jones; Lan Lan; Linda McCall; Mark W Dewhirst; Oana Craciunescu; Paul Stauffer; Vlayka Liotcheva; Allison Betof; Kimberly Blackwell Journal: Int J Hyperthermia Date: 2010 Impact factor: 3.914
Authors: Taher A Al-Tweigeri; Dahish S Ajarim; Adher A Alsayed; Mohamed M Rahal; Mohamed O Alshabanah; Asma M Tulbah; Osama A Al-Malik; Doha M Fatani; Gamal A El-Husseiny; Naser B Elkum; Adnan A Ezzat Journal: Med Oncol Date: 2009-06-13 Impact factor: 3.064
Authors: Anita Mamtani; Andrea V Barrio; Tari A King; Kimberly J Van Zee; George Plitas; Melissa Pilewskie; Mahmoud El-Tamer; Mary L Gemignani; Alexandra S Heerdt; Lisa M Sclafani; Virgilio Sacchini; Hiram S Cody; Sujata Patil; Monica Morrow Journal: Ann Surg Oncol Date: 2016-05-09 Impact factor: 5.344
Authors: Kenneth E Pengel; Bas B Koolen; Claudette E Loo; Wouter V Vogel; Jelle Wesseling; Esther H Lips; Emiel J Th Rutgers; Renato A Valdés Olmos; Marie Jeanne T F D Vrancken Peeters; Sjoerd Rodenhuis; Kenneth G A Gilhuijs Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-29 Impact factor: 9.236
Authors: Marieke E Straver; Tjeerd S Aukema; Renato A Valdes Olmos; Emiel J T Rutgers; Kenneth G A Gilhuijs; Margaret E Schot; Wouter V Vogel; Marie-Jeanne T F D Vrancken Peeters Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-04 Impact factor: 9.236
Authors: R E Coleman; M C Winter; D Cameron; R Bell; D Dodwell; M M Keane; M Gil; D Ritchie; J L Passos-Coelho; D Wheatley; R Burkinshaw; S J Marshall; H Thorpe Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640